dolutegravir + tenofovir disoproxil fumarate + emtricitabine

This drug is a fixed-dose combination of three antiretroviral agents used in the treatment of HIV-1 infection. It contains: - Dolutegravir, an integrase strand transfer inhibitor (INSTI) that blocks the action of HIV integrase, preventing viral DNA from integrating into the host genome. - Tenofovir disoproxil fumarate (TDF), a nucleotide reverse transcriptase inhibitor (NRTI) that inhibits HIV reverse transcriptase by competing with natural substrates and causing chain termination during viral DNA synthesis. - Emtricitabine, also an NRTI, which similarly inhibits reverse transcriptase and terminates viral DNA elongation. The combination is used as part of antiretroviral therapy for adults and pediatric patients with HIV-1 infection. It is typically administered orally once daily as a single tablet. The regimen provides potent suppression of HIV replication and is recommended by major guidelines as a first-line option for initial therapy in many settings[3].

Other names

dolutegravir/tenofovir disoproxil fumarate/emtricitabineDTG/TDF/FTC